OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Neurology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Healthy brain in a healthy body	3549
Diversity and inclusion in neurosurgery	785
Score fluctuation might be associated with a higher placebo rate in the RAISE trial	537
Challenges of Parkinson's disease GWASs in African people	506
The hidden unity of the mind	477
Kerstin Hellwig: educating on multiple sclerosis and pregnancy	440
Treatment of asymptomatic carotid stenosis in SPACE-2	410
With thanks to our peer reviewers in 2022	342
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	321
Transforming amyotrophic lateral sclerosis into a liveable disease	303
Elevating the wellbeing of neurologists	299
Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke	294
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial	287
The reality of multiple sclerosis assessment in middle-income countries	285
The debate on how to protect and restore brain health	282
Disparities in neurosurgical care for traumatic brain injury	266
Advanced consent for acute stroke trials	263
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	234
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	226
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-in	222
The challenge of pregnancy in women with multiple sclerosis	217
Cardiovascular disease after traumatic brain injury: the heart of the matter	212
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	211
Maxime Baud	203
A neurological journey to save lives in Haiti	195

Medieval treatment of epilepsy in England	193
Lightning progress in child neurology in the past 20 years	190
Tanuja Chitnis: on role models, family, and multiple sclerosis	168
Spiralling towards an ending	168
Dancing with paper	160
Anatomy embroiders function in Purkinje cells	155
Malformations of cortical development as models of altered brain excitability	154
Seizure prevention in patients with intracerebral haemorrhage	153
Maeike Zijlmans	147
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA	146
Vittorio Marchi's staining	146
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	145
The wisdom of our mentors: clinical pearls in movement disorders	143
Pseudomedicine for sports concussions in the USA	142
Licence to practise	141
Our Dementia Choir hits the right notes	136
CGRP-targeted drugs for migraine: still many uncertainties	131
Fetal exposure to antiseizure medications: reassurance and concerns	131
Elisaveta Sokolov	128
Sex, gender, and the cost of neurological disorders	127
Journey down memory lane	125
V Wee Yong: a journey of rediscovery	124
Giuseppe Citerio's neurocucina	123
Form and function in the brain	122
The social network of functional neurological disorder	121
Tatyana Shelkovnikova	121
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	117
COP27 Climate Change Conference: urgent action needed for Africa and the world	117
The link between blood pressure and Alzheimer's disease	116
Multiple sclerosis: two decades of progress	115
Traumatic brain injury research: homogenising heterogeneity	111
α-synuclein seed amplification in Parkinson‘s disease	109
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	108
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	105
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage	102
PROMISE of low-cost immunosuppressants for myasthenia gravis	97
The predictive value and clinical use of the neurological pupillary index – Authors' reply	96
Monitoring patients with severe traumatic brain injury	95
Innovation in the prevention of neurological diseases	93
Advancing seizure forecasting from cyclical activity data	92
A contentious FDA ruling for Alzheimer's disease	92
Dementia care: beyond a diagnosis	92
Huntington's disease: disappointments and new beginnings	90
Climate change and neurology: time to talk and to act	89
Lessons and future directions for GBA1-targeting therapies	88
Georgios Tsivgoulis: in top gear	87
Intracranial pressure monitoring and unfavourable outcomes	86
20th Anniversary photography competition: neurology for zoomers	80
The East Asian Parkinson Disease Genomics Consortium	79
Headache in 2021: clinical, biological, and genetic advances	79

Leriglitazone: frustration and hope in adrenoleukodystrophy	79
Intra-arterial bone marrow mononuclear cells for stroke	77
From film to philanthropy	76
A disease-specific therapy in facioscapulohumeral muscular dystrophy	75
Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention	75
Appropriate selection of participants for clinical trials in epilepsy	73
Treatment of asymptomatic carotid stenosis	73
Traumatic brain injury advances since 2017: what has changed?	73
Forging ahead in haemorrhagic stroke research	70
A neurotransmitter with a fascinating story	68
What we remember	67
Healthy eating for secondary stroke prevention	67
Association of Pick's disease with the MAPT H2 haplotype	67
Amyotrophic lateral sclerosis: a lesson in translation	65
Neurological disorders caused by novel non-coding repeat expansions: clinical features and differential diagnosis	65
Carotid artery overtreatment in the USA	65
New therapies for Pompe disease: are we closer to a cure?	64
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	63
Could SARS-CoV-2 cause tauopathy?	63
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	63
Making brain health a global priority	63
WHO launches its Global Action Plan for brain health	62
Dementia diagnosis in the anti-amyloid era	60
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	60
Speculation on the transmissibility of Alzheimer's disease	60
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study	59
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	59
The African Dementia Consortium	58
Mitochondrial disease in adults: recent advances and future promise	58
Treatment of acute subdural haematoma – Authors' reply	57
Elinor Ben-Menachem: a talented risk-taker with great results	57
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials	57
Extended-interval dosing of natalizumab in NOVA – Authors' reply	56
Dementia research in 2022: advancing steadily on reflection	56
Neuroscience highlights in 2022: cytoskeletal transport	56
A spirited community that knows how to fight	55
The EyeVu Consortium for global neurosurgery	55
Multidisciplinary care for amyotrophic lateral sclerosis	54
Angela Vincent: a pioneer of immune-mediated disease	54
Addressing neurological burden in the Americas	53
Concerns with the new biological research criteria for synucleinopathy	53
Azathioprine and mycophenolate mofetil in myasthenia gravis – Authors' reply	52
Cristina Tassorelli: making a difference in headache research	52
Apomorphine infusion for improving sleep in Parkinson's disease	52
Implications of the KIWE trial for low-income and lower-middle-income countries	52
Women in Neurosurgery: breaking barriers	52
Autoimmune encephalitis: chasing a moving target	51
CSF factors in memory function	51
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	51
LRRK2 and survival in progressive supranuclear palsy	49
Rare diseases: we need to think about climate change too	48
The Brain Research Africa Initiative (BRAIN)	48
Cerebral amyloid angiopathy criteria: the next generation	48
Treatment for Alzheimer's disease: time to get ready	48
Management of atherosclerotic extracranial carotid artery stenosis	47
Has the time come to redefine Parkinson's disease?	47
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses	46
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	44
A new classification for diagnosis of optic neuritis	44
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease – Authors' reply	44
The evolving paradigm of Alzheimer's disease diagnosis	44
Application of diagnostic criteria for optic neuritis	43
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial	42
Lecanemab slows Alzheimer's disease: hope and challenges	42
The prognostic potential of pupillometry in patients with acute brain injury	42
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	40
Inspiring the next generation	40
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	39
Integrated approach to stroke burden: are we doing enough?	39
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	39
Time to end the stigma of epilepsy	38
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	37
Advances in Alzheimer's disease research over the past two decades	37
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	37
Chronic effects of inflammation on tauopathies	37
Multiple sclerosis progression: time for a new mechanism-driven framework	36
Neuromodulation in epilepsy: state-of-the-art approved therapies	36
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	35
The neuropsychiatry of Parkinson's disease: advances and challenges	35
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	34

Effects of climate change on the brain: an environmental neurology perspective	32
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study	32
Frank Longo: taking on Alzheimer's disease	32
Surgical treatment for chronic subdural haematoma	32
Carpal tunnel syndrome: updated evidence and new questions	31
Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series	31
The elusive foundations of creativity	31
The relevance of social and commercial determinants for neurological health	30
Increasing diversity in dementia research	30
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	30
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	29
γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational	28
The shortage of thrombolytics for stroke: a call for action	28
Sleep function: an evolutionary perspective	27
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	27
Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care	27
Diagnosis and classification of optic neuritis	26
Progression of cerebral amyloid angiopathy: a pathophysiological framework	25
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	25
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis	24
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	23
Drug resistance in epilepsy	23
A biological classification of Huntington's disease: the Integrated Staging System	23
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study	22
Moyamoya disease: diagnosis and interventions	22
Correction to Lancet Neurol 2021; 20: 762–72	21
Anti-CD19 CAR T cells for refractory myasthenia gravis	21
Correction to Lancet Neurol 2021; 20: 1038–47	21
Correction to Lancet Neurol 2024; 23: 168–77	21
Correction to Lancet Neurol 2022; 21: 42–52	21
Important considerations for children with non-dystrophic myotonia	20
Differential diagnosis of suspected multiple sclerosis: global health considerations	20
RAB32 mutation in Parkinson's disease	20
Correction to Lancet Neurol 2024; 23: 393–403	20
Considerations for future trials in cerebral cavernous malformations – Authors' reply	20
Amyloid removal and the appearance of brain volume loss	20
The Yaoundé Declaration	20
Health as a philosophical idea	20
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia	20
Global burden of stroke: dynamic estimates to inform action	19
Correction to Lancet Neurol 2023; 22: 1160–206	19
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	19
Correction to Lancet Neurology 2021; 19: 1033–42	19
Correction to Lancet Neurol 2021; 20: 703–04	19
Improving access to medicines for neurological disorders	19
Correction to Lancet Neurol 2022; published online Sept 29. https://doi.org/10.1016/ S1474-4422(22)00309-X	19
Correction to Lancet Neurol 2021; 20: 448–59	18
Nursing homes with a difference: the outdoors inside	18
Ischaemic stroke in 2024: progress on multiple fronts	18
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	18
Correction to Lancet Neurol 2025; 24: 65–76	17
Reconsidering prourokinase for acute ischaemic stroke	17
Jules Froment's neurological statuettes	17
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease	17
CNS disease associated with enhanced type I interferon signalling	17
Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial	16
Highlights in traumatic brain injury research in 2023	16
Mar Tintoré, Mar Mediterráneo	16
Effects of spaceflight on the brain	16
Anticoagulants to prevent recurrent non-cardioembolic stroke	16
Changing views of disability	16
Considering the neurological health needs of LGBTQIA people	16
Walker's miracle of science	16
Neurology is not a heartless business	15
Action needed on social and commercial determinants of neurological health – Authors' reply	15
Detecting awareness after acute brain injury	15
Neuromuscular junctions: mind meeting matter	15
Venglustat in GBA1-related Parkinson's disease – Authors' reply	14
The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study	14
Alzheimer's disease: a history revisited	14
A multipronged approach to advancing palliative care for people with intellectual disabilities	14
Rigmor Højland Jensen: the headache warrior	14
WHO considers multiple sclerosis treatments essential	14
Prevention of dementia with holistic brain health	14
Trials in intracerebral haemorrhage: a path to success?	13
A chilly tale of dementia	13
Correction to Lancet Neurol 2019; 18: 329–31	13
Thank you to The Lancet Neurology's peer reviewers in 2022	13
Prioritising integration of palliative care to prevent suffering	13
Pierre Amarenco: the persistent pioneer	13
Esme Ekizoglu Turgut	13
Forecasting seizure risk in adults with focal epilepsy: a development and validation study	12
The need for a better global dementia response	12
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase	12
Karen Duff: blazing a path in dementia research	12
Asymptomatic carotid stenosis and stroke risk – Authors' reply	11
Improving prognostication after severe brain injury	11
The promises and pitfalls of brain repair	11
Idiopathic hypersomnia: does first to approval mean first-line treatment?	11
Safe laboratory management of prions and proteopathic seeds	11
20 years of hammers, pins, and hope	11
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	11
Management of Alzheimer's disease takes a leap forward	11
A celebration of neurology in the 21st century	11
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	11